Cargando…

Imaging Biomarkers and Pathobiological Profiling in a Rat Model of Drug-Induced Interstitial Lung Disease Induced by Bleomycin

A large number of systemically administered drugs have the potential to cause drug-induced interstitial lung disease (DIILD). We aim to characterize a model of DIILD in the rat and develop imaging biomarkers (IBs) for detection and quantification of DIILD. In this study, Sprague–Dawley rats received...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahmutovic Persson, Irma, Falk Håkansson, Hanna, Örbom, Anders, Liu, Jian, von Wachenfeldt, Karin, Olsson, Lars E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317035/
https://www.ncbi.nlm.nih.gov/pubmed/32636756
http://dx.doi.org/10.3389/fphys.2020.00584
_version_ 1783550542708998144
author Mahmutovic Persson, Irma
Falk Håkansson, Hanna
Örbom, Anders
Liu, Jian
von Wachenfeldt, Karin
Olsson, Lars E.
author_facet Mahmutovic Persson, Irma
Falk Håkansson, Hanna
Örbom, Anders
Liu, Jian
von Wachenfeldt, Karin
Olsson, Lars E.
author_sort Mahmutovic Persson, Irma
collection PubMed
description A large number of systemically administered drugs have the potential to cause drug-induced interstitial lung disease (DIILD). We aim to characterize a model of DIILD in the rat and develop imaging biomarkers (IBs) for detection and quantification of DIILD. In this study, Sprague–Dawley rats received one single dose of intratracheal (i.t.) bleomycin and were longitudinally imaged at day 0, 3, 7, 14, 21, and 28 post dosing, applying the imaging techniques magnetic resonance imaging (MRI) and positron emission tomography (PET)/computed tomography (CT). Bronchoalveolar lavage fluid (BALF) was analyzed for total protein and inflammatory cells. Lungs were saved for further evaluation by gene analysis using quantitative-PCR and by histology. Lung sections were stained with Masson’s-Trichrome staining and evaluated by modified Ashcroft score. Gene expression profiling of inflammatory and fibrotic markers was performed on lung tissue homogenates. Bleomycin induced significant increase in total protein concentration and total cell count in bronchoalveolar lavage (BAL), peaking at day 3 (p > 0.001) and day 7 (p > 0.001) compared to control, respectively. Lesions measured by MRI and PET signal in the lungs of bleomycin challenged rats were significantly increased during days 3–14, peaking at day 7. Two subgroups of animals were identified as low- and high-responders by their different change in total lung volume. Both groups showed signs of inflammation initially, while at later time points, the low-responder group recovered toward control, and the high-responder group showed sustained lung volume increase, and significant increase of lesion volume (p < 0.001) compared to control. Lastly, important inflammatory and pro-fibrotic markers were assessed from lung tissue, linking observed imaging pathological changes to gene expression patterns. In conclusion, bleomycin-induced lung injury is an adequate animal model for DIILD studies and for translational lung injury assessment by MRI and PET imaging. The scenario comprised disease responses, with different fractions of inflammation and fibrosis. Thereby, this study improved the understanding of imaging and biological biomarkers in DIILD and lung injury.
format Online
Article
Text
id pubmed-7317035
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73170352020-07-06 Imaging Biomarkers and Pathobiological Profiling in a Rat Model of Drug-Induced Interstitial Lung Disease Induced by Bleomycin Mahmutovic Persson, Irma Falk Håkansson, Hanna Örbom, Anders Liu, Jian von Wachenfeldt, Karin Olsson, Lars E. Front Physiol Physiology A large number of systemically administered drugs have the potential to cause drug-induced interstitial lung disease (DIILD). We aim to characterize a model of DIILD in the rat and develop imaging biomarkers (IBs) for detection and quantification of DIILD. In this study, Sprague–Dawley rats received one single dose of intratracheal (i.t.) bleomycin and were longitudinally imaged at day 0, 3, 7, 14, 21, and 28 post dosing, applying the imaging techniques magnetic resonance imaging (MRI) and positron emission tomography (PET)/computed tomography (CT). Bronchoalveolar lavage fluid (BALF) was analyzed for total protein and inflammatory cells. Lungs were saved for further evaluation by gene analysis using quantitative-PCR and by histology. Lung sections were stained with Masson’s-Trichrome staining and evaluated by modified Ashcroft score. Gene expression profiling of inflammatory and fibrotic markers was performed on lung tissue homogenates. Bleomycin induced significant increase in total protein concentration and total cell count in bronchoalveolar lavage (BAL), peaking at day 3 (p > 0.001) and day 7 (p > 0.001) compared to control, respectively. Lesions measured by MRI and PET signal in the lungs of bleomycin challenged rats were significantly increased during days 3–14, peaking at day 7. Two subgroups of animals were identified as low- and high-responders by their different change in total lung volume. Both groups showed signs of inflammation initially, while at later time points, the low-responder group recovered toward control, and the high-responder group showed sustained lung volume increase, and significant increase of lesion volume (p < 0.001) compared to control. Lastly, important inflammatory and pro-fibrotic markers were assessed from lung tissue, linking observed imaging pathological changes to gene expression patterns. In conclusion, bleomycin-induced lung injury is an adequate animal model for DIILD studies and for translational lung injury assessment by MRI and PET imaging. The scenario comprised disease responses, with different fractions of inflammation and fibrosis. Thereby, this study improved the understanding of imaging and biological biomarkers in DIILD and lung injury. Frontiers Media S.A. 2020-06-19 /pmc/articles/PMC7317035/ /pubmed/32636756 http://dx.doi.org/10.3389/fphys.2020.00584 Text en Copyright © 2020 Mahmutovic Persson, Falk Håkansson, Örbom, Liu, von Wachenfeldt and Olsson. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Mahmutovic Persson, Irma
Falk Håkansson, Hanna
Örbom, Anders
Liu, Jian
von Wachenfeldt, Karin
Olsson, Lars E.
Imaging Biomarkers and Pathobiological Profiling in a Rat Model of Drug-Induced Interstitial Lung Disease Induced by Bleomycin
title Imaging Biomarkers and Pathobiological Profiling in a Rat Model of Drug-Induced Interstitial Lung Disease Induced by Bleomycin
title_full Imaging Biomarkers and Pathobiological Profiling in a Rat Model of Drug-Induced Interstitial Lung Disease Induced by Bleomycin
title_fullStr Imaging Biomarkers and Pathobiological Profiling in a Rat Model of Drug-Induced Interstitial Lung Disease Induced by Bleomycin
title_full_unstemmed Imaging Biomarkers and Pathobiological Profiling in a Rat Model of Drug-Induced Interstitial Lung Disease Induced by Bleomycin
title_short Imaging Biomarkers and Pathobiological Profiling in a Rat Model of Drug-Induced Interstitial Lung Disease Induced by Bleomycin
title_sort imaging biomarkers and pathobiological profiling in a rat model of drug-induced interstitial lung disease induced by bleomycin
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317035/
https://www.ncbi.nlm.nih.gov/pubmed/32636756
http://dx.doi.org/10.3389/fphys.2020.00584
work_keys_str_mv AT mahmutovicperssonirma imagingbiomarkersandpathobiologicalprofilinginaratmodelofdruginducedinterstitiallungdiseaseinducedbybleomycin
AT falkhakanssonhanna imagingbiomarkersandpathobiologicalprofilinginaratmodelofdruginducedinterstitiallungdiseaseinducedbybleomycin
AT orbomanders imagingbiomarkersandpathobiologicalprofilinginaratmodelofdruginducedinterstitiallungdiseaseinducedbybleomycin
AT liujian imagingbiomarkersandpathobiologicalprofilinginaratmodelofdruginducedinterstitiallungdiseaseinducedbybleomycin
AT vonwachenfeldtkarin imagingbiomarkersandpathobiologicalprofilinginaratmodelofdruginducedinterstitiallungdiseaseinducedbybleomycin
AT olssonlarse imagingbiomarkersandpathobiologicalprofilinginaratmodelofdruginducedinterstitiallungdiseaseinducedbybleomycin